Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 9, 2009

View Archived Issues

Merck KGaA presents novel PDK1 inhibitors with oncolytic properties

Novel gamma-secretase inhibitors patented by Schering-Plough for treating Alzheimer's disease

New orexin receptor antagonists imparted by GSK for sleep disorders

Cyclopamine blocks serous ovarian tumor growth in vivo

U.S. Department of Health & Human Services divulges new antibacterial PSMalpha peptides

Oramed completes proof-of-concept study of ORMD-0802

EGEN-001 with chemotherapy shows activity in ovarian cancer

Fourth quarter highlights at AstraZeneca

ImClone continues development of arylphthalazine VEGFR-2 inhibitors

Cell-based gene therapy effective in SCID due to ADA deficiency

Fujifilm raises equity stake in Perseus Proteomics to focus on antibody-based therapeutics

Esteve Teijin Healthcare: A new venture to improve home respiratory therapy

PharmaMar receives Swiss approval for Yondelis in soft tissue sarcoma

Tibotec seeks traditional approval from FDA for Intelence

Cyclacel advances sapacitabine pivotal trial plan in hematological malignancies

Idenix and GlaxoSmithKline sign worldwide license agreement for IDX-899

FDA accepts for review NDA for intranasal ROX-888

Johnson & Johnson presents an update on Invega and paliperidone palmitate

Tigris files IND for anticancer drug GGTI-2418

FDA approves ATryn to prevent thromboembolic events

Nplate approved in the E.U. for the treatment of ITP

Orexo enters into exclusive development agreement for its OX-17 program

Daiichi Sankyo returns U.S. and European marketing rights for Collategene to AnGes

Bayer Schering initiates CHEST-1 and PATENT-1 phase III clinical trials of riociguat

Inhibitors of HIV reverse transcriptase under development at Yale University

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...